RxDoctor Payments Data

Stacy Marsh

Family · Norwich, CTNPI 1659433092

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 604 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,722in general payments, 2019–2025

Across 604 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$926
  • GSK$848
  • Boehringer Ingelheim$822
  • Astellas Pharma US Inc$787
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$10,18095%
  • Education$5435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,722 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter234$164,960
OzempicSemaglutide97$111,719
JardianceEmpagliflozin59$60,185
JanuviaSitagliptin Phosphate63$49,193
Nurtec OdtRimegepant Sulfate22$46,235
RybelsusSemaglutide29$38,751
MounjaroTirzepatide28$31,159
EliquisApixaban31$27,012
FarxigaDapagliflozin Propanediol35$24,021
TradjentaLinagliptin20$23,431
MyrbetriqMirabegron35$22,123
TrulicityDulaglutide22$22,084
Tresiba Flextouch U-200Insulin Degludec14$17,154
Breo ElliptaFluticasone/Vilanterol26$15,953
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$14,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$848$195,823287 claims
Novo NordiskOzempic, Rybelsus$1,103$150,470126 claims
Boehringer IngelheimJardiance, Tradjenta$822$83,61679 claims
PfizerNurtec Odt, Eliquis$121$73,24653 claims
Lilly USA, LLCMounjaro, Trulicity$576$53,24350 claims
MerckJanuvia$34$49,19363 claims
AstraZenecaFarxiga, Breztri Aerosphere$926$33,11848 claims
Astellas Pharma US IncMyrbetriq$787$22,12335 claims
Johnson & JohnsonXarelto$55$7,05811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →